Our Products
Loans
Cards
Insurance
Investment
Stock Market
Electronics Mall
CIBIL Score
Knowledge Centre
Academy 
Calculators
Our Services
My Account
Do not call
En
Concord Drugs Ltd. Share Price
Day's Range
Day's Range
Low
₹
High
₹
Price Summary
| Previous Close | ₹81.00 |
|---|---|
| Day's Range | ₹80.60 - ₹83.39 |
| Open | ₹83.39 |
| 52 Week Range | ₹29.00 - ₹92.52 |
| Volume | 1,235 |
| Market Cap | ₹0.00 |
Stocks Summary
| Trade Value ( ₹ in Lacs) | 1.00 |
|---|---|
| Market Cap (₹ in Mn) | 0.00 |
| Dividend Yield(%) | 0.00 |
| Price/Earning (TTM) | 184.85 |
| TTM EPS (₹) | 0.43 |
| P/E Ratio | 92.45 |
| Book Value(₹) | 2.27 |
| PAT Margin (%) | 0.74 |
| Face Value (₹) | 10.00 |
| ROCE(%) | 5.19 |
Financials
| Particulars | QTR FY (₹ in Millions) | Annual FY (₹ in Millions) |
|---|---|---|
| Net sales | 107.74 | 432.7 |
| Expenses | N/A | N/A |
| PBT | 5.21 | 5.58 |
| Operating profit | 0.0 | 0.0 |
| Net profit | 2.22 | 4.2 |
About Concord Drugs Ltd.
| Founded | 1995 |
|---|---|
| Managing Director | S Nagi Reddy |
Peer Comparision
| Stocks Name | Market Cap (Cr)(₹) | Market Price (₹) | 52 Week Low-High (₹) |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | 4,47,032.09 | 1,879.90 | 1,548.00 - 1,548.00 |
| Divi's Laboratories Ltd. | 1,83,758.68 | 6,755.00 | 5,636.50 - 5,636.50 |
| Torrent Pharmaceuticals Ltd. | 1,49,223.98 | 4,386.00 | 3,102.00 - 3,102.00 |
| Apollo Hospitals Enterprise Ltd. | 1,16,692.75 | 8,077.00 | 6,696.50 - 6,696.50 |
| Cipla Ltd. | 1,16,214.23 | 1,431.55 | 1,165.70 - 1,165.70 |
| Dr. Reddy's Laboratories Ltd. | 1,08,739.11 | 1,336.95 | 1,148.40 - 1,148.40 |
| Lupin Ltd. | 1,03,230.20 | 2,273.90 | 1,836.80 - 1,836.80 |
| Max Healthcare Institute Ltd. | 1,02,166.27 | 1,050.05 | 903.00 - 903.00 |
| Mankind Pharma Ltd. | 1,01,634.21 | 2,507.00 | 1,909.70 - 1,909.70 |
| Zydus Lifesciences Ltd. | 99,747.98 | 1,011.25 | 835.50 - 835.50 |
No Records Found
Latest News
Senores Pharmaceuticals informs about press release
Rainbow Children's Medicare informs about board meeting
Mangalam Drugs and Organics informs about newspaper advertisement
Pursuant to Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Mangalam Drugs and Organics has informed that it enclosed copies of newspaper advertisement published in Financial Express and Loksatta, both in which Audited Financial Results (Standalone and Consolidated) of the Company for the quarter and financial year ended March 31, 2026 have been published. The aforesaid results have been approved by the Board of Directors in its meeting held on Thursday, May 14, 2026.
The above information is a part of company’s filings submitted to BSE.
Star Imaging and Path Lab board to consider audited financial results
Solara Active Pharma Sciences informs about allotment of shares
Solara Active Pharma Sciences has informed that pursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (‘SEBI Listing Regulations’) and Regulation 10(c) of Securities and Exchange Board of India (Share Based Employee Benefits and Sweat Equity) Regulations, 2021, (‘SEBI SBEB & SE Regulations’), the Board of Directors have approved the allotment of 2,200 Equity Shares of face value Rs 10 each fully paid up against the exercise of vested Options of Solara Employee Stock Option Plan 2018. The equity shares so allotted under the aforesaid Scheme, shall rank with the existing equity shares of the Company in all respects. Consequent to the aforesaid allotment, the paid‐up share capital of the Company will accordingly increase, as details enclosed. In terms of Regulation 10(c) read with Part - E of the SEBI SBEB & SE Regulations, the details of the shares allotted are enclosed as ‘Annexure-A; and the details required as per Master circular no. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 are enclosed as ‘Annexure -B’.
The above information is a part of company’s filings submitted to BSE.
No Records Found
Sign in to Unlock Offers!
We don't SPAM
Frequently Asked Questions
The current share price of Concord Drugs Ltd. is ₹81.00 as of 2026-05-15.
The market capitalisation of Concord Drugs Ltd. is ₹104.62 as of 2026-05-14.
The 1-year return of Concord Drugs Ltd. is 50.29% as of 2025-05-14.
The P/E ratio of Concord Drugs Ltd. is 92.45 as of 2026-05-15.
The 52-week high and low of Concord Drugs Ltd. are ₹92.52 and ₹29.00, respectively, as of 2026-05-15.
Disclaimer
All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.
The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.
Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform.
